What is Diagnocure, Inc. (DGCRF) stock price today?

Diagnocure, Inc. (DGCRF) is currently trading at $0.00.

What is DGCRF P/E ratio?

Diagnocure, Inc.'s P/E ratio is 0.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is DGCRF return on equity (ROE)?

Diagnocure, Inc.'s return on equity (ROE) is -400.00%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Diagnocure, Inc.'s market cap?

Diagnocure, Inc. has a market capitalization of $21520.

OTC · Medical - Specialties

Diagnocure, Inc. (DGCRF) Stock

$0.00 OTC: DGCRF Healthcare

Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis.

Valuation

Metric	Value
Price	$0.00
Market Cap	$21520
P/E Ratio	0.00
P/B Ratio	0.02
P/S Ratio	0.02
EPS (TTM)	$-0.11
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-400.00%
ROA	-200.00%
ROCE	-103.56%
Gross Margin	-100.00%
Operating Margin	-200.00%
Net Margin	-400.00%
Debt/Equity	0.00
Current Ratio	4.00

Annual Financials (USD)

Metric	2011	2012	2013	2014	2015
Revenue	$1.0M	$2.0M	$1.0M	$1.0M	$1.0M
Operating Profit	$-4.0M	$-4.0M	$-4.0M	$-2.0M	$-2.0M
Net Profit	$-1.0M	$-4.0M	$-4.0M	$-2.0M	$-4.0M
EPS	$-0.04	$-0.09	$-0.08	$-0.06	$-0.11
Op Margin	-361.2%	-152.0%	-541.0%	-376.9%	-294.0%

Balance Sheet (USD)

Metric	2011	2012	2013	2014	2015
Total Assets	$16.0M	$11.0M	$8.0M	$6.0M	$2.0M
Total Liabilities	$2.0M	$1.0M	$1.0M	$0	$0
Cash	$7.0M	$1.0M	$1.0M	$1.0M	$1.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

PlanHub Earns #1,357 Ranking on the 2026 Inc. 5000, Celebrating Six Consecutive Years Among America's Fastest-Growing Private Companies PR Newswire · Aug 11, 2026 ContourGlobal to deploy 3GWh CATL batteries in UK, Greece and Chile Power Technology · Aug 11, 2026 CWST Q2 Deep Dive: Acquisition Integration and Pricing Execution Drive Growth Amid Cost Headwinds StockStory · Aug 11, 2026 Global Data Center UPS Market - $30.7B Opportunity by 2031 as Power Demand Reaches 28.3 GW - Arizton PR Newswire · Aug 11, 2026 Beyond SPF: Y.O.U Presents New SUNBRELLA™ PhotoshieldX Technology at Connex-C Asia 2026 to Redefine the Future of Tropical Skincare PR Newswire · Aug 11, 2026

Cash Flow (USD)

Metric	2011	2012	2013	2014	2015
Operating Cash Flow	$-2.0M	$-3.0M	$-2.0M	$-2.0M	$-1.0M
Investing Cash Flow	$7.0M	$-3.0M	$2.0M	$2.0M	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$5.0M	$-6.0M	$1.0M	$0	$-1.0M
Free Cash Flow	$-3.0M	$-3.0M	$-2.0M	$-2.0M	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.19
FCF Yield	-3988.06%
Quick Ratio	4.00
Interest Coverage	-256.68
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CBDHFHempfusion Wellness Inc.	$0.00	—	0.00	$1635	0.00%
CTBO	$1.01	+0.00%	—	$22769	0.00%
HGENQHumanigen, Inc.	$0.00	—	—	$23816	0.00%
MGFRFMagForce AG	$0.00	—	—	$11973	0.00%
NLBSNutraLife BioSciences, Inc.	$0.00	—	—	$17662	0.00%

About Diagnocure, Inc.

Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.

Diagnocure, Inc. (DGCRF) stock trades at $0.00 with a market capitalization of $21520. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.02, price-to-sales of 0.02. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Diagnocure, Inc. generates a return on equity (ROE) of -400.00%, return on capital employed of -103.56%, an operating margin of -200.00%, a net profit margin of -400.00%.

Official website: www.diagnocure.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides